Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference
September 13 2022 - 7:30AM
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish
Seshadri, Chief Executive Officer of Abeona, will participate in a
panel discussion at the Cantor Fitzgerald Cell and Genetic
Medicines Conference on Thursday, September 15, 2022. The panel
discussion, entitled, “Late Stage and Commercial Gene & Cell
Therapy Warriors: How They Got to/Crossed the Finish Line,” is
scheduled to begin at 2:30 p.m. ET. The Company will also
participate in one-on-one investor meetings at the conference.
Those interested in attending the panel discussion or requesting
a one-on-one meeting with Abeona are encouraged to contact their
Cantor Fitzgerald representative.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical
company developing cell and gene therapies for serious diseases.
Abeona’s lead clinical program is EB-101, its investigational
autologous, gene-corrected cell therapy for recessive dystrophic
epidermolysis bullosa in Phase 3 development. The Company’s
development portfolio also features AAV-based gene therapies for
ophthalmic diseases with high unmet medical need. Abeona’s novel,
next-generation AAV capsids are being evaluated to improve tropism
profiles for a variety of devastating diseases. Abeona’s fully
integrated cell and gene therapy cGMP manufacturing facility
produces EB-101 for the pivotal Phase 3 VIITAL™ study and is
capable of clinical and potential commercial production of
AAV-based gene therapies. For more information, visit
www.abeonatherapeutics.com.
Investor and Media Contact:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024